ArticleClinical and experimental medicine2026
Optimized interpretation of p53 immunohistochemistry for prediction of TP53 mutations and patient survival in DLBCL.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The prognostic value of p53 immunohistochemical (IHC) staining in diffuse large B cell lymphoma (DLBCL) remains controversial. We retrospectively included 149 patients who were diagnosed with and treated for DLBCL at Peking Union Medical College Hospital (PUMCH). TP53 IHC staining and TP53 sequencing was performed from paraffin-embedded biopsy tissues. Clinical information including basic characteristics and outcome was collected for data analysis. An internal validation cohort of 58 patients with DLBCL was also retrospectively recruited in PUMCH. In the 149 DLBCL cohort, TP53 mutations were detected in 40 patients, with 29 harboring damaging mutations. TP53 mutation showed no significant correlation with either PFS (p = 0.065) or OS (p = 0.140), whereas damaging TP53 mutations were significantly correlated with poor PFS (p = 0.008) and OS (p = 0.030). A novel P53 IHC reading pattern was identified. Using the percentage of cells with strong p53 intensity (p53str) as IHC readout, we discovered a significant correlation of high p53str staining (p53strhigh) with TP53 damaging mutation (p = 0.001). Importantly, p53strhigh was significantly correlated with poorer PFS (p < 0.001) and OS (p = 0.001). The estimated 5-year PFS and 5-year OS rates were 58.8% and 74.3% for p53strlow, and 17.9% (p = 0.001) and 30.1% (p < 0.001) for p53strhigh. Incorporating p53str into the IPI score significantly improved risk stratification of DLBCL. An internal validation cohort of 58 DLBCL patients confirmed the prognostic value of p53str. These results indicate p53str as a promising readout for p53 IHC staining and support its role as a surrogate marker for TP53 mutations and patient survival in DLBCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.